David J. Mazzo, Ph.D.
Chief Executive Officer

David J. Mazzo, Ph.D., joined Regado Biosciences in August 2008 as President and Chief Executive Officer. Dr. Mazzo brings to Regado almost 25 years of experience in the pharmaceutical industry, most recently as President and CEO of Æterna Zentaris. Dr. Mazzo also has served as President and CEO of Chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group, after holding senior management and executive positions in R&D at Schering-Plough, Hoechst Marion Roussel and Rhone-Poulenc Rorer.

Dr. Mazzo is a pharmaceutical executive and strategic leader with broad technical and managerial experience gained from working in a variety of multicultural and multilingual environments in the USA, Canada, Europe and Asia. He is recognized for his strong strategic, scientific and regulatory expertise, upon which he has amassed a track record of approximately 25 years of successful global product development, registration and launch. Dr. Mazzo has proven himself to be a change leader uniquely adept at driving working groups to new levels of performance and achievement.

Dr. Mazzo currently is Non-Executive Chairman of pSivida, Inc., and a Director of Avanir Pharmaceuticals. He earned a Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University. In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Michael A. Metzger, MBA
President and Chief Operating Officer

Michael A. Metzger joined Regado in December 2013 as President and Chief Operating Officer. Mr. Metzger has nearly 20 years of experience within the life sciences and pharmaceuticals industries. Mr. Metzger has a distinguished track record of building value for shareholders through product and company acquisitions as well as organic growth by leveraging pharmaceutical partnerships.

Prior to joining Regado, from April 2011 to November 2013, Mr. Metzger held the position of Executive Vice President and Chief Operating Officer at Mersana Therapeutics, a private, venture-financed, biopharmaceutical company developing next generation antibody drug conjugates for oncology. At Mersana, he established key business alliances and helped architect the strategic direction, financing and growth of the business which led to Mersana being named a Fierce15 Biotech Company in 2012. Prior to joining Mersana in early 2011, Mr. Metzger held senior positions within Business Development and led Mergers and Acquisitions at Forest Laboratories, Inc. where he completed deals with numerous specialty pharmaceutical and biotechnology companies including Cerexa, Novexel, Ironwood Pharmaceuticals and Clinical Data, Inc.

Prior to his time at Forest, Mr. Metzger was Vice President Corporate Development at Onconova Therapeutics, Inc., from 2001 until 2006. At Mesa Partners, Inc., a venture capital firm from 1997 to 2001, he was Managing Director.  Mr. Metzger served as a member of the Board of Directors of Response Genetics, Inc., a company focused on the development and commercialization of molecular diagnostic tests for cancer from 2010 to November 2013. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.

Steven L. Zelenkofske, D.O., F.A.C.C.
Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer

Steven L. Zelenkofske, D.O., F.A.C.C. joined Regado in December 2008 as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer. Dr. Zelenkofske has led clinical programs for 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine.

Most recently, Dr. Zelenkofske served as Vice President, Cardiovascular/Thrombosis Medical Unit – US at Sanofi-Aventis Pharmaceuticals and, prior to this, as Vice President of Clinical Sciences and Chief Patient Safety Officer for Boston Scientific Corporation’s Cardiac Rhythm Management (CRM) Group. At both companies, Dr. Zelenkofske led the development and implementation of cardiovascular pre- and post-market clinical strategy. Prior to this, he was a senior director with Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division, attaining the position of Senior Medical Director, US Clinical Development, Hypertension and CV Section Head. Dr. Zelenkofske also served as Director of CV Research and Clinical Director of Electrophysiology Laboratory at the Heart Care Group, where he was a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT.

Dr. Zelenkofske is the author or co-author of numerous articles published in professional journals, including the New England Journal of Medicine, Circulation, American Heart Journal and the European Heart Journal. He is a practicing electrophysiologist at Lehigh Valley Hospital in Allentown, Pennsylvania, and serves as an associate professor of medicine at the College of Medicine of the Pennsylvania State University/Hershey Medical Center and for the Philadelphia College of Osteopathic Medicine. Dr. Zelenkofske earned Bachelor of Science and Master’s degrees in biochemistry and immunopharmacology at Emory University. He received a medical degree from the Philadelphia College of Osteopathic Medicine and holds certifications in clinical cardiac electrophysiology, cardiology and internal medicine.

Alexander R. Giaquinto, Ph.D.
Senior Vice President of Regulatory Affairs and Quality Assurance and Chief Compliance Officer

Alexander R. Giaquinto, Ph.D., joined Regado Biosciences in November 2008 as Senior Vice President of Regulatory Affairs and Quality Assurance. Dr. Giaquinto brings to Regado over 38 years of experience in the pharmaceutical industry, including 30 years at Schering-Plough where he held executive management positions in the areas of Worldwide Regulatory Affairs and Compliance. At Schering-Plough, Dr. Giaquinto was instrumental in establishing the development and regulatory strategies for the approvals of 74 New Drug Applications (NDAs) and Supplements, nine Biologic License Applications (BLAs) and 28 Abbreviated NDAs.

Dr. Giaquinto currently is a Director of SemBioSys Genetics, Biothera and Endoceutics. He is also a member of the Advisory Boards of Allozyne Inc and EndoCeutics and served on, as well as chaired, the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Giaquinto earned a Bachelor of Science in Pharmacy from St. John’s University and a Ph.D. in Pharmaceutics from the University of Connecticut.

Chris Rusconi, Ph.D.
SVP Discovery/Preclinical Development and Chief Scientific Officer

Chris Rusconi Ph.D. is a co-founder of Regado and serves as the Company’s Chief Scientific Officer.

Prior to joining Regado in 2003, Dr. Rusconi was Director of Research for the Program in Combinatorial Therapeutics and Assistant Research Professor of Surgery at Duke University Medical Center. As Director of Research, he focused on the discovery and early development of nucleic acid-based therapeutics by integrating input from leading clinicians with the technologic know-how of basic and translational scientists. Dr. Rusconi has authored or co-authored more than 20 peer-reviewed publications, including works appearing in Nature, Circulation and the Journal of Clinical Investigation. He is the co-inventor of the Regado technology and the Company’s lead program, the REG1 Anticoagulation System, and has led the development of this program from discovery into phase 2 testing.

Dr. Rusconi earned a Bachelor of Science degree in the Honors Program in Cellular Biology from the University of Kansas, and a Ph.D. in Molecular and Cellular Biology from the University of Colorado, Boulder. He continued his training as a Jane Coffin Childs postdoctoral fellow at Duke University Medical Center.

Christopher Courts, MBA, CPA
Vice President of Finance

Christopher Courts, MBA, CPA brings 13+ years of financial management experience in both public & private markets to Regado. Prior to joining Regado in April 2006, Mr. Courts served as a Director with Deltacom where his responsibilities included corporate budgeting and the oversight of financial operations. His experience with ITCD also included managing Sarbanes-Oxley compliance, as well as several merger & acquisition opportunities culminating with the merger of Business Telecom, Inc. and ITC Deltacom in 2003.

During his career, Mr. Courts has provided senior financial leadership advice to multiple biotechnology companies with a focus on strategic business planning, cash management, and financial reporting. Mr. Courts has a strong track record of reducing risk,
ensuring sound financial practices, and delivering process improvements that lower costs, increase profits, and secure organizations’ future success. Prior consulting activities have focused on early to mid-stage Life Science organizations, and relationships
include venture-backed entities throughout the southeast.

Mr. Courts is licensed as a Certified Public Accountant in North Carolina, and he received his B.A. and M.B.A. degrees in Finance from Marshall University in Huntington, WV.